The FDA recorded a supplement to abbreviated new drug application ANDA 206741 for itraconazole, held by Alembic, on 14 September 2026.
This is an administrative entry against an existing generic rather than an approval, an indication change or a safety communication. Supplements to an abbreviated application typically cover manufacturing, specification or labelling changes, and the record carries no clinical detail beyond the application and the holder. Nothing about itraconazole prescribing, dosing or monitoring changes because of it.
The reason it is worth a line is supply. Itraconazole is a workhorse in Indian practice — dermatophytosis, allergic bronchopulmonary aspergillosis, chronic pulmonary aspergillosis — and the holder here is an Indian manufacturer. Where a generic's continuity matters to a treatment course that runs for months, the application record is the primary source; a change to it is not clinical news but it is supply news.
- No change to itraconazole indications, dosing or drug-interaction checks follows from this
- Continue to check itraconazole interactions individually — the list is long and the entry does not alter it
- For Indian supply questions, CDSCO rather than the FDA is the relevant authority
- Treat long antifungal courses as a supply-planning problem as well as a clinical one
Why it matters
Antifungal continuity over a months-long course is a real clinical risk, and supply news is where it shows up first.
Don't overread it
An ANDA supplement is administrative — it is neither a new approval nor a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free